R01 CA055306/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2007	2
2009	2
2010	2
2011	3
2012	6
2013	3
2024	0

1

Cai Z, Zhang H, Liu J, Berezov A, Murali R, Wang Q, Greene MI. Cai Z, et al. Semin Cell Dev Biol. 2010 Dec;21(9):961-6. doi: 10.1016/j.semcdb.2010.09.005. Epub 2010 Sep 17. Semin Cell Dev Biol. 2010. PMID: 20850557 Free PMC article. Review.

2

Progress of molecular targeted therapies for prostate cancers.

Fu W, Madan E, Yee M, Zhang H. Fu W, et al. Biochim Biophys Acta. 2012 Apr;1825(2):140-52. doi: 10.1016/j.bbcan.2011.11.003. Epub 2011 Nov 29. Biochim Biophys Acta. 2012. PMID: 22146293 Free PMC article. Review.

3

ErbB receptors: from oncogenes to targeted cancer therapies.

Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI. Zhang H, et al. J Clin Invest. 2007 Aug;117(8):2051-8. doi: 10.1172/JCI32278. J Clin Invest. 2007. PMID: 17671639 Free PMC article. Review.

4

The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Freudenberg JA, Wang Q, Katsumata M, Drebin J, Nagatomo I, Greene MI. Freudenberg JA, et al. Exp Mol Pathol. 2009 Aug;87(1):1-11. doi: 10.1016/j.yexmp.2009.05.001. Epub 2009 May 18. Exp Mol Pathol. 2009. PMID: 19450579 Free PMC article. Review.

5

Challenges in the clinical utility of the serum test for HER2 ECD.

Lam L, McAndrew N, Yee M, Fu T, Tchou JC, Zhang H. Lam L, et al. Biochim Biophys Acta. 2012 Aug;1826(1):199-208. doi: 10.1016/j.bbcan.2012.03.012. Epub 2012 Apr 3. Biochim Biophys Acta. 2012. PMID: 22521738 Free PMC article. Review.

6

Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivin.

Berezov A, Cai Z, Freudenberg JA, Zhang H, Cheng X, Thompson T, Murali R, Greene MI, Wang Q. Berezov A, et al. Oncogene. 2012 Apr 12;31(15):1938-48. doi: 10.1038/onc.2011.377. Epub 2011 Sep 5. Oncogene. 2012. PMID: 21892210 Free PMC article.

7

Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity in immune suppression.

Li B, Saouaf SJ, Samanta A, Shen Y, Hancock WW, Greene MI. Li B, et al. Curr Opin Immunol. 2007 Oct;19(5):583-8. doi: 10.1016/j.coi.2007.07.006. Epub 2007 Aug 20. Curr Opin Immunol. 2007. PMID: 17703930 Review.

8

Structural and biological features of FOXP3 dimerization relevant to regulatory T cell function.

Song X, Li B, Xiao Y, Chen C, Wang Q, Liu Y, Berezov A, Xu C, Gao Y, Li Z, Wu SL, Cai Z, Zhang H, Karger BL, Hancock WW, Wells AD, Zhou Z, Greene MI. Song X, et al. Cell Rep. 2012 Jun 28;1(6):665-75. doi: 10.1016/j.celrep.2012.04.012. Epub 2012 Jun 15. Cell Rep. 2012. PMID: 22813742 Free PMC article.

9

Reversion of the ErbB malignant phenotype and the DNA damage response.

Runkle EA, Zhang H, Cai Z, Zhu Z, Karger BL, Wu SL, O'Rourke DM, Zhou Z, Wang Q, Greene MI. Runkle EA, et al. Exp Mol Pathol. 2012 Dec;93(3):324-33. doi: 10.1016/j.yexmp.2012.09.007. Epub 2012 Sep 27. Exp Mol Pathol. 2012. PMID: 23022358 Free PMC article. Review.

10

Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancers.

Du T, Nagai Y, Xiao Y, Greene MI, Zhang H. Du T, et al. Exp Mol Pathol. 2013 Aug;95(1):38-45. doi: 10.1016/j.yexmp.2013.04.003. Epub 2013 May 2. Exp Mol Pathol. 2013. PMID: 23644046 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

14 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year